ARS Pharmaceuticals, Inc.
SPRYHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Headquartered within the healthcare sector, ARS Pharmaceuticals, Inc. focuses on Biotechnology services and products. ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company carries a $933.5M market cap, placing it firmly in the small-cap category. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Market Cap
$933.5M
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
-9.82
EPS (TTM)
$-2.21
EPS (Fwd)
$-0.96
ROE
-136.4%
ROA
-41.1%
Cash
$201.0M
Total Debt
$171.2M
Free CF
-$98.3M
52W Change
-34.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $201.0M in cash comfortably exceeding the $171.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$98.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -136.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $1.3M to $84.3M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ARS Pharmaceuticals, Inc. and its sector.